XanRelax and Addall

Case Name (Date)

Brown et al. v. ZMB Enterprises LLC
22-cv-54, S.D. Cal.
(Jan. 2022)

Product/Service

XanRelax and Addall

Allegations

Misleadingly labeling products as “dietary supplements” when they contain illegal ingredients and thus do not meet the definition of “dietary supplement” under federal law

Misleadingly using the name XanRelax to make consumers believe the product provides benefits similar to the prescription drug Xanax

Misleadingly using the name Addall to make consumers believe the product provides benefits similar to the prescription drug Adderall

Falsely marketing products as able to treat, cure, and prevent diseases, including depression, anxiety, and ADHD, and without FDA approval to do so

Status

Voluntarily dismissed When a complaint is dismissed without prejudice, an amended version of the complaint can be refiled.